Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Reisser

Surgery Maryville, TN Medical Doctor

NPI 1104904028 CMS profile 94980

250 Bmh Physicians Office Bldg, Maryville, TN 37804

Open in the dashboard

General payments

$5,196

157 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Reisser of Maryville, TN is reported in the CMS Open Payments database as having received $5,196 across 157 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $463 13
2024 General $358 18
2023 General $762 26
2022 General $454 15
2021 General $714 19
2020 General $580 28
2019 General $1,863 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Reisser
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to John Reisser were reported at $463. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year John Reisser Surgery median Middle half National median
2019 $1,863 $253 $82–$1,521 $163
2020 $580 $131 $40–$706 $114
2021 $714 $168 $50–$904 $132
2022 $454 $224 $76–$1,218 $149
2023 $762 $253 $82–$1,255 $160
2024 $358 $279 $90–$1,381 $164
2025 $463 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Silk Road Medical, Inc. $1,453 12 payments
  2. Shockwave Medical, Inc $584 31 payments
  3. Endologix, Inc. $455 6 payments
  4. W. L. Gore & Associates, Inc. $427 12 payments
  5. Cardinal Health 200, LLC $313 18 payments
  6. Penumbra, Inc. $238 4 payments
  7. Medtronic Vascular, Inc. $208 15 payments
  8. Bard Peripheral Vascular, Inc. $174 5 payments
  9. Abiomed $141 1 payment
  10. Medtronic, Inc. $129 6 payments
  11. Other $1,075 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,481 153 payments
  2. Travel and Lodging $714 4 payments
Products named General payments · program years 2019–2025
  1. ENROUTE 0.014 Guidewire $936 6 payments
  2. ENROUTE Transcarotid Stent System $936 6 payments
  3. ENROUTE Transcarotid Neuroprotection System Carotid Artery Disease $936 6 payments
  4. ENHANCE Transcarotid Peripheral Access Kit Carotid Artery Disease $936 6 payments
  5. ENROUTE Transcarotid Stent $517 6 payments
  6. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $517 6 payments
  7. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $474 25 payments
  8. ENHANCE Transcarotid Peripheral Access Kit Cardiology/Vascular Diseases $321 4 payments
  9. ENROUTE .014 Guidewire $321 4 payments
  10. Indigo System $225 3 payments
  11. Other $2,986 116 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

304

Median for General Surgery: 59

Drug cost

$39,961

Median for General Surgery: $393

Branded share of claims

74%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 18 $19,777
Eliquis Apixaban Brand 28 $18,413
Clopidogrel Clopidogrel Bisulfate Brand 163 $1,430
Atorvastatin Calcium Generic 21 $170
Oxycodone Hcl Generic 58 $110
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 16 $60

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 90 billing codes

Paid by Medicare

$142,625

Medicare's payments for the services billed

Medicare patients

189

Average age 76

Services billed

930

81 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 56%
Arthritis 52%
Chronic kidney disease 50%
Diabetes 48%
COPD 44%
Atrial fibrillation 38%
Heart failure 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

157 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record